GlassScriptPhysician profile
David D Gayle
NPI 1336133131
$7,483.56
in general payments reported to CMS, 2019-2025
46 companies · $1,390 in 2025
The $1,390 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $1,005 · 2021: $890 · 2022: $759 · 2023: $1,134 · 2024: $1,263 · 2025: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,786.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $570.18 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $562.75 | 2019-2025 | Repatha, Prolia, Evenity |
| Novartis Pharmaceuticals Corporation | $550.40 | 2019-2025 | |
| Amarin Pharma, INC. | $472.16 | 2019-2023 | |
| Lilly USA, LLC | $375.02 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $344.27 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $340.84 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $311.38 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $309.01 | 2019-2025 | Cds - Mct/Cem Monitoring |
| Pfizer INC. | $306.83 | 2019-2025 | |
| Abbott Laboratories | $299.79 | 2019-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $269.75 | 2019-2024 | Xarelto |
| Abbvie INC. | $259.91 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.18 | 2019-2024 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $212.10 | 2019-2021 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $184.53 | 2023-2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.61 | 2022-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $165.72 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Gilead Sciences, INC. | $163.13 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $152.84 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $131.10 | 2019-2024 | Veozah |
| Galvanize Therapeutics, INC | $130.43 | 2025 | Aliya System |
| Neurocrine Biosciences, INC. | $104.49 | 2024-2025 | Ingrezza |
| Dexcom, INC. | $88.17 | 2022-2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $80.03 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $66.88 | 2019-2025 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $52.09 | 2019 | |
| Daiichi Sankyo INC. | $50.30 | 2025 | Injectafer |
| Esperion Therapeutics, INC. | $49.76 | 2023-2025 | Nexletol |
| Insulet Corporation | $46.41 | 2023 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $46.14 | 2022-2024 | Trintellix |
| Arbor Pharmaceuticals, INC. | $45.69 | 2019-2021 | |
| Corium, LLC | $45.19 | 2023 | Azstarys |
| Philips North America LLC | $41.24 | 2020-2025 | Src Undivided |
| Glaxosmithkline, LLC. | $32.09 | 2023-2024 | Shingrix, Boostrix, Arexvy |
| Medtronic, INC. | $27.66 | 2021 | |
| Lundbeck LLC | $27.13 | 2025 | Rexulti |
| Elutia, INC. | $24.76 | 2019 | |
| Radius Health, INC. | $20.60 | 2025 | Tymlos |
| Baudax Bio INC. | $19.96 | 2022 | |
| Abiomed | $19.88 | 2020 | |
| Chiesi USA, INC. | $18.90 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.12 | 2022 | |
| Medtronic Vascular, INC. | $14.72 | 2019 | |
| Seqirus USA INC | $14.52 | 2025 | Flucelvax |
| Axsome Therapeutics, INC. | $8.90 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gayle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.